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Abstract 
Hypervaccination against infectious diseases is a radically new efficient strategy of preventive vaccination. Its objective is 
specific abrogation of innate susceptibility of the organism to the disease achieved by blockage of the pathogen specific binding 
sites (receptors) on the surface of target cells by the anti-receptors of the vaccine. The new strategy is based on competition 
between the anti-receptors of the vaccine and those of the pathogen for the receptors on target cells. The mechanism of 
hypervaccination is a rapid maximal saturation of the target cells receptors with a massive dose of anti-receptors contained in a 
live or inactivated vaccine. Protection of the naturally susceptible organism against infection initially occurs by the mechanism of 
homologous interference at the stage of the pathogen’s binding to the target cell rather than by reactions of adaptive immunity. At 
a later stage, early protection is followed by a long-term intense immune response with a marked seroconversion. Thus, a high 
dose vaccination confers protection in two stages, interference at the receptor binding level and immune response. Administering 
a safe vaccine with a high content of anti-receptors protects naturally susceptible animals against disease and death at challenge 
12-72 hrs after vaccination with no chronic infection establishing. An apparent resistance of the organism against a severe 
challenge soon after vaccination is likely to be due to a full or virtually full saturation of the target cells receptors with the 
vaccine anti-receptors. The efficiency of prompt protection in field conditions has first been shown in the eradication of classical 
swine fever (CSF) in two countries, Russia and Belarus. 
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1. Introduction 
2. Vaccine based control is considered one of the outstanding achievements of biological science characteristic of 
which is an immediate use of developments made in various fields of science. Due to that, a great success has been 
made in the fight against many major infectious diseases of animals and humans. Thus, in 1979, smallpox was 
eradicated as a result of a global vaccination. Many other dangerous diseases, e.g. poliomyelitis, influenza, measles, 
rabies, have been effectively controlled. In the developed economies, specific control of the farm animal infections 
represents an integrate part of industrial animal breeding. Some vaccines are manufactured in millions and billions 
of doses.  
3. Despite the obvious progress in vaccine development and tremendous results of vaccination, it is still essentially 
based mostly on the principles of conventional vaccine control and unable to solve many problems of inflectional 
pathology. In this paper, the main results of the researches on development of a new, non-immunologic vaccination 
strategy, are presented. The idea of the new vaccination strategy is creation of prompt, rapidly developing specific 
protection of the organism without participation of the immune system. The possibility of a rapid protection has 
been experimentally shown for various viral and bacterial diseases of animals.  
4. The first illustrative results on rapid protection were obtained in experiments on immunization of poultry against 
Newcastle disease (ND) with a live vaccine from the H strain. A virulent ND virus strain caused disease and death 
of chickens on days 5 to 6 after challenge. Vaccinating 8 hrs. after or at the same time with injection of the virulent 
virus failed to protect the chickens from disease and death. However, all the chickens vaccinated and challenged 
with the virulent NDV strain 8, 16, 24, 32, 40 and 48 hrs. after vaccination were protected. In the authors’ opinion, 
the protective effect soon after the vaccination was due to a competitive blocking (interference) of the susceptible 
cells by the vaccine virus1. 
5. Our research group conducted a study of the protective properties of an inactivated vaccine against avian 
spirochaetosis. The vaccine represented freeze dried blood of chickens experimentally infected with a virulent field 
strain of spirochaeta and contained >107 spirochaetas per 1 ml.. Freeze drying inactivated spirochaetas, but 
preserved their antigenic properties. A numerous group of chickens were simultaneously administered the 
inactivated vaccine and 1 through 5 days later were challenged with the virulent spirochaeta strain (10 LD100), 25 
chickens each day. On day 1 after vaccination, 20% of chickens were resistant to infection, on day 2, 80%  were 
resistant and on days 3, 4 and 5 all the vaccinated fowl were resistant to infection. All the immune chickens 
remained clinically healthy and did not contain spirochaetas in the blood, whereas all the control chickens (25) fell 
sick and died within 4 to 6 days after challenge. The dry vaccine stored at 22 – 260C remained immunogenic over 4 
years (the observation term)2. According to other authors, the resistance of vaccinated chickens to a spirochaetosis 
challenge developed in 48 to 72 hours3.  
6. Live vaccines CL, GP, LK against classical swine fever (CSF) administered in high doses protected pigs against 
the disease at a challenge 3 to 4 days after vaccination3, 4, 5. The CL vaccine administered in a dose of 400 PD50 in 
field conditions raised protective immunity in >94% pigs3. The immunizing properties of the LK live vaccine were 
studied in pigs by challenge (104 LD50) dependent on the vaccine dose and the time after vaccination. The vaccine in 
a dose of 102 TCID50 failed to protect the animals in 7 days but protected 28 days after vaccination. In a dose of 104 
TCID50, the vaccine did not protect the pigs in 3 days but protected 10 days after vaccination. The increase of the 
vaccine dose 1,000 and 10,000 times (105 TCID50 and 106 TCID50) provided protection of the pigs against the 
disease in 3 and 2 days respectively6.  
7. The main aim of this study was approbating the new vaccination strategy in the program on classical swine fever 
(CSF) eradication conducted in two countries. The choice of CSF for trial of the vaccination strategy is explained by 
the wide distribution of the disease, high economic losses and, above all, the impossibility of CSF eradication from 
industrial pig raising by conventional vaccination7, 8. The success of the eradication program was due to the choice 
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of the new strategy (called ‘hypervaccination’) using an efficacious live vaccine, reliable laboratory diagnostic 
techniques9, 10, 11 as well as an exceptional economic interest in CSF eradication of the two economies12.  
8. Substantiation of application. Classical swine fever (CSF) is the most harmful disease of swine that results in 
serious economic losses in many pig raising countries. It occurs in the acute, chronic and unapparent forms and is 
characterized by a high contagiousness. Lethality varies greatly and may reach 100%. According to OIE, CSF is 
classified in the group of the particularly dangerous diseases that should be under special control of the national 
veterinary service8. 
9. Specific prophylaxis has long been an important means of CSF control. A new era in specific prevention of CSF 
began in the 1960s with the development of live anti-CSF vaccines. However, eradication of the disease proved a 
complicated problem. Various live vaccines made from the C strain were conventionally used in Europe, Asia and 
South America. The wide application of the live anti-CSF vaccines led to a marked decrease of economic losses and 
improvement of the epidemic situation with CSF. Systematic vaccination was followed by a drop of morbidity and 
sometimes even by apparent ‘vanishing’ of the disease across vast areas. However, sometime later it reappeared8,13, 
14. 
10. The international experience on CSF control has shown that the existing live vaccines inoculated in a low dose 
(102 TCID50) create a life-long immunity in pigs under experimental conditions, but are unable to eradicate the 
disease in densely swine populated areas or on industrial farms7,8,13,14,15. Immune response to the live vaccines is 
characterized by a long development period and a broad variability14,16. The latter is the reason of insufficiency of 
the conventional vaccination for eradication of CSF. The example of an insufficient “group” immunity against CSF 
in big herds comes from the experience  in Mexico where five live vaccines protected the pigs in the experiment, 
whereas only 64 % of the animals vaccinated with the same preparations under farm conditions were fully 
protected15. The main reason for persistence of CSF in the industrial pig raising economies despite conventional 
vaccination is a low immunity in a subpopulation (approximately 10 to 15%) of sows13, 17, which are latently 
infected and transplacentally transmit virulent CSFV at any stage of pregnancy14, 18. Consequently, some piglets are 
born latently infected and represent a source of CSFV for life. Against the backdrop of vaccination, on large infected 
piggeries (30 to 280 thousand animals), disease and death of 10 to 20 % pigs aged mostly 50-70 days were 
constantly recorded. On those farms, an insufficient immune protection in 10 to 18 % sows was reported (VNA 
titers <1:32)12, 17, 19. On average, 12% piglets were born CSFV infected, on some farms, this figure might reach 20 to 
25%. Therefore, systematic conventional immunizationwith theLK live vaccine (inoculation dose 103 TCID50)had 
proved unable to eradicate CSF mainly due to insufficient immune response in a small part of sows that developed 
latent infection and transplacentally transmitted the virus to the progeny. 
11. Impossibility of CSF eradication by means of traditional vaccination  led the EU nations to the last resort: 
destroying all the swine in the CSF affected regions. In 1993-98, nearly 14 million swine were culled in total, with 
the economic losses exceeding 5 billion euros7, 8. 
12. Due to the economic reasons, Russia, like many other nations, could not use the experience of the EU (and the 
USA20) on CSF eradication based on mass depopulation of swine. The only possibility of preserving the pig raising 
industry affected by CSF remained traditional vaccination. In particular, in China, home to some 500 million swine, 
the LC live vaccine has been applied since 195421. In the USSR and later in Russia and Belarus, over the last 40 
years protection of the CSF affected pig raising industry has been based on conventional use of the LK live vaccine 
in a dose of 103 TCID5013, 22. Over the indicated period, more than 1.5 billion doses of this vaccine were 
manufactured and used unadvertised12.  
13. The existing situation led us to the necessity of a completely new solution for eradication of CSF based on 
vaccination. A new strategy of preventive vaccination provisionally called ‘hypervaccination13, 19, 23, 24 was based on 
inoculation of a high amount of the specific anti-receptors with the vaccine in order to promptly remove the natural 
susceptibility to CSF. The prompt protection of pigs in experimental and field conditions was likely due to blockage 
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of the specific receptors for CSF virus, which abolished the infectious virus binding and infecting susceptible cells.   
The main objective of hypervaccination was ceasing the circulation of the virulent CSF virus in affected herds by a 
rapid creation of maximal insusceptibility to the infection in pigs. The regular vaccination using the LC and LK live 
vaccines (102 and 103 TCID50 respectively) had been unable to solve this problem for decades. The choice of 
hypervaccination using a safe concentrated live vaccine was the primary condition for the problem solution12, 13, 19, 22. 
The factors favoring the success were the reliable laboratory diagnostic techniques9, 10, 11 and a high economic 
interest in CSF eradication of the two nations12. 
14. The experience in eradication of CSF in field conditions showed that a 10-times increase of the LK vaccine dose 
failed to eradicate the disease even in relatively small herds (5 to 7 thousand pigs). This agreed with other 
researchers’ data17. So in the further practice, the vaccine was administered in a dose 100 times higher than that 
regularly used (103 TCID50) and 1000 times higher compared with the dose (102 TCID50) adopted for the majority of 
live vaccines worldwide13, 15, 24. Given a marked increase of the inoculation dose for the LK vaccine and therefore 
higher costs of CSF vaccination, the technology for manufacture of the vaccine from the LK strain of CSF virus was 
upgraded and the vaccine virus activity was raised 10 times. The upgraded vaccine was titled ‘KS’22. Nearly 40 
million doses of KS were manufactured. 
15. Results 
16. Safety and efficiency.  A particular attention was paid to safety of the new vaccine preparation for animals being 
inoculated. In the first experiment, the sows were inoculated with the LK-KS vaccine in a dose of 103 TCID50 15 
days prior to insemination. Some of them were revaccinated in a dose of 104 and 105 TCID50 on days 80 to 95 of 
pregnancy. The intensity of the immune response was assessed by VNA titers. The VNA titers were measured on 
days 2 and 30 after farrowing in the sows and on days 2 to 4 and 25 to 30 after birth in the newborn piglets.  In each 
group, blood sera were collected from main sows and gilts and from piglets of their litters. The results of the 
experiment showed that a considerable number of sows (~ 15%) immunized in a dose of 103 TCID50 only, failed to 
develop a protective level of VNAs. The revaccination of sows in a dose of 105 TCID50 approximately 30 days 
before farrowing led to a protective level of immunity in all the revaccinated sows and their progeny with no 
negative effect on their physiology (Table 1). In the second experiment, the seroconversion and clinical features 
were assessed in sows and 18- to 23-days-old piglets inoculated with KS in a dose of 106 TCID50. The  
17.  
18. Table 1. Hypervaccination of heavily pregnant sows and their reproductivity  
 
Group No 
Vaccination of 
sows, 15 days 
prior to 
insemination 
Revaccination of 
sows on day 85-90 
of pregnancy 
Number 
of sows 
farrowed 
Number of 
piglets born 
Number 
of piglets 
per one sow 
1  
103TCID50 
104TCID50 324 2,823 8,7 
2 105TCID50 216 1,827 8,4 
 
3 
No revaccination 
(control) 
 
360 
 
3,536 
 
8,5 
19.  
20. seroconversion was measured in 8 animals form each age group 30 days after inoculation. VNAs were detected 
in high titers (1:40 – 1:640) in the adult animals, whereas in the piglets the titers were lower (1:20 – 1:320) most 
likely due to the colostral immunity background (Table 2). All the vaccinated animals felt normal with no clinical 
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disorders. The results of the two experiments showed that the KS vaccine in a dose of 106 TCID50 (which is 1,000 
higher than usual) was completely safe for swine of various age.   
21.  
22. Table 2. Antibody response in swine of various groups to a higher dose (106 TCID50) of the KS vaccine  
Group 
No 
Animals vaccinated Number of 
animals 
Antibody titer in 30 days 
1 Main sows on days 85-90 of pregnancy 17 1:80 – 1:640 (1:350) 
2 Main sows, 2-3 days after farrowing 155 1:40 – 1:640 (1:340) 
3 Piglets,18-23 days old 33 1:20 – 1:320 (1:90) 
23. Comment.  Average antibody titers are given in brackets 
24.  
25.  The next two experiments were carried out to evaluate the efficacy of the KS vaccine. First, a group of 
sows were inoculated in a dose of 103 TCID50 15 days prior to insemination. Some of them were revaccinated in a 
dose of 105 TCID50 around day 90 of pregnancy.  The VNA titers were measured on days 2 and 30 after farrowing in 
sows and gilts and on days 2 to 4 and 25 to 30 in newborn piglets. On the base of the VNA titers the intensity of 
immune response was assessed11. The results showed that the level of VNA in a majority of sows (~15%) vaccinated  
26. Table 3. Influence of hypervaccination of deeply pregnant sows on the intensity of antibody immune response in 
the mothers and progeny 
Vaccination of sows, time 
point and dose 
 
Sows, 
2-3 days after farrowing 
 
Piglets of various age 
 
15 days 
before 
insemination 
 
30 days 
before 
farrowing 
 
 
Group 
 
 
Number 
Number of 
animals with 
various VNA 
titers 
 
Number 
 
Age,   
days 
Number of 
piglets with 
various VNA 
titers 
>1:32 <1:16 >1:32 <1:16 
 
103 
TCID50 
 
__ 
Main sows 10 7 3 10 2-4 8 2 
10 25-30 4 6 
Gilts 10 5 5 10 2-4 5 5 
10 25-30 3 7 
 
103 
TCID50 
 
105 
TCID50 
Main sows 10 10 0 10 2-4 10 0 
10 25-30 7 3 
Gilts 10 10 0 10 2-4 10 0 
10 25-30 10 0 
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in a dose of 103 TCID50 only was below the protective value of 1:32. Piglets born to those sows also had low levels 
of colostral antibodies. The revaccination of the sows around day 90 of pregnancy in 105 TCID50 provided protection 
of all the sows and their progeny with no harm to their health (Table 3). 
27.  Second, three groups of seronegative sows were vaccinated in a dose of 105 TCID50. Group 1 sows were 
vaccinated 21 days prior to insemination, group 2 were vaccinated around day 90 of pregnancy, group 3 were double 
vaccinated at the indicated time points. The blood sera from sows were collected prior to and on days 2, 30 and 60 
after the last vaccination, the blood sera from newborn piglets were collected on days 2, 30 and 40 after birth. All 
the high-dose vaccination schemes did not affect the physiologic status and reproductive function of the pigs. All the 
vaccinated animals developed a pronounced antibody response that provided  specific protection of the whole herd 
during the observation period and protected the newborn piglets for 40 days after birth. The strongest response 
developed in the group 3 sows (double vaccinated).  
28.  The general conclusion from the series of experiments is that hypervaccination against CSF is safe and 
highly efficacious. The intensity of immune response depends on the vaccine dose. 
29. Prompt protection. In the experimental trials, seronegative pigs aged 75 to 80 days were vaccinated followed by 
a challenge. The KS vaccine was administered in doses of 104, 105 and 106 TCID50 to four pigs each dose. 72 hrs 
later all the vaccinated and two non-vaccinated (control) pigs were challenged with virulent CSF in 104 LD100. On 
the day of challenge all the animals remained seronegative to CSF virus. The control pigs fell sick and died from 
CSF on days 9 and 11 after challenge. All the pigs vaccinated in 104 TCID50 fell sick and died from CSF on days 14 
and 19. The pigs vaccinated in 105 and 106 TCID50 remained healthy and survived (Table 4).  
30.  The results of this experiment showed a direct dependence of the time of protection onset on the vaccine 
dose. In doses of 105 and 106 TCID50 the KS vaccine within 72 hrs. protected all the animals not only from the 
disease, but also from grafting of virulent CSF virus. As a result of hypervaccination, the natural sensitivity of the 
pigs to CSF virus infection vanished rapidly in the absence of virus neutralizing antibodies.  
31.  
32. Table 4. Inhibition of natural sensibility to CSF in pigs vaccinated against CSF dependent on the vaccine dose   
 
Vaccine dose, 
TCID50 
 
Number of 
pigs 
Time 
between 
vaccination 
and challenge 
Result of challenge 
 
Infected 
 
Fell sick 
 
Died 
104 3  
72 
4 4 4 
105 3 4 0 0 
106 3 4 0 0 
Non-
vaccinated 
(control) 
 
2 
 
___ 
 
2 
 
2 
 
2 
33.  
34. Eradication of CSF from the pig raising industry of the two economies. Hypervaccination of pigs in affected 
industrial piggeries began in 1996-1997 in order to eradicate the disease from the industrial pig raising. All the sows 
on the affected farms previously vaccinated in 103 TCID50 (some in 105 TCID50) before insemination, were 
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revaccinated in >105 TCID50 no later than day 90 of pregnancy. The presence or absence of CSF in the herd was 
estimated based on results of both clinical observations and laboratory diagnostics. The blood from pigs of all age, 
organ samples from miscarriages, sick, fallen and forcedly killed pigs were analyzed by PCR. In some cases, PLA 
was used for detection of CSF virus10. The fact of eradication was concluded based on the results of recurring 
diagnostics.  
35. As the first step, hypervaccination was tested on three large-scale farms (20, 30 and 50 thousand pigs) 
characterized by chronic CSF and 20 to 30% losses, especially at the stage of growth (50- to 70-days-old). On each 
farm, hypervaccination took 5 to 6 months to carry out. As a result, all the three farms became CSF-free. The results 
of a prototype laboratory diagnostic study are shown in Table 5.  
36.  
37. Table 5. CSF virus (CSFV) bearing on a farm before and after hypervaccination  
 
Animal group 
Presence of CSFV in the blood 
Before 
hypervaccination,PCR 
After hypervaccination 
PCR PLA 
Sows, 2 weeks after 
farrowing 
1/10 0/20 0/20 
Piglets 2-days-old 2/10 0/20 0/20 
Piglets 15-days-old 3/10 0/20 0/20 
Piglets 
45 to 50-days-old 
2/10 0/20 0/20 
Piglets 
75 to 80-days-old 
0/10 0/20 0/20 
Feeder pigs 0/10 0/10 0/10 
38. Comment. The numerator designates the number of positive results, the denominator designates the number of animals 
studied  
39.  
40. Second, seven industrial farms (60-130 pigs each) were subject to hypervaccination for nearly 2 years. As a 
result, the results of the first trials were confirmed.  The recurring studies of samples from the seven farms did not 
find virulent CSF virus. The PCR study of 200 blood samples from colostrum-free piglets confirmed the absence of 
the infection.   
41. The positive results of CSF eradication from the previous two trials encouraged a mass  hypervaccination on all 
affected industrial farms in the two countries. The final stage of hypervaccination took several years (2006 – 2010) 
and ended successfully. The positive effect of the large scale hypervaccination was confirmed by final expert trials 
of over 400  tissue samples from formerly CSF affected piggeries (50 to 130 thousand pigs each). The PCR results 
fully corresponded to those of the epidemiologic survey. The absence of the disease on the farms was additionally 
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confirmed by natural biological control keeping vaccinated pigs together with non-vaccinated ones (indicator 
groups).  
42. The absence of CSF over the last 7 years (2006-2013) in the pig raising industry in the two economies has been 
confirmed by numerous studies using the up-to-date techniques adopted for CSF diagnosis. Many years of applying 
the new vaccination strategy in field conditions with use of the live KS vaccine have proven its safety and high 
efficacy for eradication of CSF on the economy scale. The analysis of the laboratory diagnostic results has shown 
that hypervaccination can do what conventional vaccine prophylactic cannot.  
43. Discussion  
44. Efficacy of the existing vaccines is based on the classic principle of immune protection, that is, induction of 
immune response to an inoculated vaccine. Immune response normally starts developing shortly after administering 
a vaccine and reaches the peak in 2 to 4 weeks. However, there are numerous experimental data suggesting that 
protection against many infections manifests as soon as in 1- to 3-days time, that is prior to developing the vaccinal 
immune response. At the moment, multiple examples of vaccine-induced early (rapid / prompt) protection of 
animals are known against various viral and bacterial diseases (Table 6). The reliability of the results has been 
confirmed by the studies where naturally susceptible animals are challenged with the respective pathogen (the 
golden standard). It is noteworthy that in the  majority of those studies the prompt protection is tested against lethal 
infections.  
45. Prompt protection develops before the onset of specific antibodies and prevents the pathogens form taking hold 
in the organism. The protection developing in 1 to 3 days after the vaccination preserves up to two years25, 26.  
46. The vaccine dose plays the crucial part in the development of rapid protection. For example, an inactivated 
vaccine against foot-and-mouth disease (FMD) protected cattle, sheep and swine from day 1-3 after inoculation in a 
dose of 30-300 PD5025, and a live vaccine against classic swine fever (CSF) was efficacious in a dose of >105 
TCID506, 12. A similar dependence was observed in experiments with a live vaccine against smallpox27 and an 
inactivated blood plasma vaccine against hepatitis B28.  
47. A number of authors working on the problem of prompt vaccinal protection supposed that this phenomenon was 
based on homologous interference between the vaccinal and pathogenic microorganisms1, 2, 29-34. The indicated 
mechanism has been confirmed by the in vitro experiments with various viruses. It has been shown that the viral 
component of an anti-FMD vaccine hinders the adsorption, entry and replication of the homologous virulent virus in 
a sensitive cell culture. The protective effect has been demonstrated to occur at the early stage of the infection25, 31. 
Empty poliovirus capsids bound to the surface of sensitive cells by the principle of saturation competed with mature 
viral particles for the binding sites on the cells35. Similarly, defective interfering particles (DIP) of influenza virus in 
MDCK cell culture prevented the reproduction of the homologous virulent virus36.  
48. The provided examples show that the time of onset and the intensity of early protection are determined by the 
amount and properties of vaccinal anti-receptors, that is, the rate of saturation of the target cells receptors. As a 
result, the natural susceptibility vanishes in 12 to 72 hrs. after vaccination, and the resistance to a challenge takes 
hold. Thus, prompt protection is a consequence of competitive interaction n the receptor / anti-receptor system based 
on homologous interference at the stage of adsorption. DIP seem to play an important part in prompt protection. 
49. The researches on prompt protection from infectious diseases have been based on studies of receptor 
interactionin the pathogen – susceptible cells system. The first studies in this direction demonstrated the difference 
in 
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50. Table 6. Examples of rapid vaccinal protection of naturally susceptible animals from infectious   
               diseases  
Disease Vaccine type Experimental animals 
Time between 
vaccination and 
protection, days 
References 
Newcastle disease Live Chickens 0,5 - 4 1,29,33,37 
Avian pox Live Chickens 3 38 
Duck plague Live Ducks 1 34 
Duck hepatitis Live Ducklings 3 37 
Classical swine fever Live Pigs 3 – 4 3, 5, 6, 12 
Rinderpest Live Cattle 2 – 4 37 
Carnivore distemper Live Dogs 2 – 4 37 
Myxomatosis Live Rabbits 2 – 4 37 
Rabbit pox Live Rabbits 2 – 4 37 
Anthrax Live Small lab animals 2 3 
Foot-and-mouth disease Inactivated Cattle, sheep, pigs 1 – 3 25, 32, 39 
 
Avian spirochaetosis 
 
Inactivated 
 
Chickens 
3 2 
2 – 3 3 
Rabbit hemorrhagic disease Inactivated Rabbits 2 26 
51.  
52. receptor specificity of human and animal influenza viruses40-42. Further studies o receptor-mediated interaction 
of pathogens and susceptible cells have contributed to general understanding of the mechanisms of infectious 
pathology including innate and adoptive immunity43-48. The selective mechanism of infecting susceptible cells 
underlies the fundamental properties of pathogens: pathogenicity and virulence; the organ and cell tropism of a 
pathogen determines the clinical features, course and outcome of the disease43, 48, 49.  
53. Studying the possibility of rapid abrogation of the natural susceptibility to infectious diseases by the means of 
hypervaccination initiates a completely new trend in specific control and eradication of infectious diseases. The 
prompt protection from an infection is likely to be due to a full or virtually full saturation of the receptors on target 
cells with the vaccinal anti-receptors. This can explain why vaccinated animals are resistant to the challenge before 
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the onset of a considerable antibody response. Therefore, safe concentrated live or inactivated vaccines are needed 
for creation of prompt protection.  
54. Until recent, specific vaccinal protection had been connected solely with the function of the organism’s immune 
system49. At the moment, it has been proved that non-immune rapid (12-72 hrs.) specific protection can be achieved 
by inoculating a high dose of anti-receptors with the vaccine. The immune response (including antibody response) 
develops later, after the onset of rapid (prompt) protection. Thus, the two stages of specific protection against 
infection can be identified, (i) receptor-interferential and (ii) immunological.   
55. Prompt specific protection is especially relevant for so-called ‘volatile’ diseases (with a short incubation period), 
and also for protection of infants as it does not depend on the immunoreactivity of an organism. Moreover, it can be 
important for slowly developing infections (like rabies) as there are evidences that the development of a disease in 
an infected organism can be stopped by inoculation of a sufficient amount (dose) of anti-receptors with the 
vaccine50.  
56. Individual variability of the immune response appears not to matter at greatly increased vaccine doses. This 
phenomenon is known as ‘phenotypic correction of the genetic control of the immune response’47. For example, a 4- 
to 10-times increased dose of a live anti-measles vaccine raised the percentage of immune children from 66-73% to 
98-100%51, and a 100-times higher dose of a live anti-CSF vaccine provided a protection from and eradication of the 
disease12. 
57. A many-year large scale experience of applying hypervaccination in practical conditions has proved its safety 
and high efficacy for eradication of CSF in the pig raising industry of Russia and Belarus. For the first time in the 
world practice the feasibility of CSF eradication by the means of hypervaccination was demonstrated. This example 
is a convincing evidence of the possibility of liquidation of dangerous infectious diseases in large populations in vast 
areas by the means of creating a prompt protection using the new vaccination strategy. Development of safe anti-
receptor vaccines can become a perfect basis for materialization of the new strategy.   
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